Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles

Med Oncol. 2015 Jul;32(7):208. doi: 10.1007/s12032-015-0652-5. Epub 2015 Jun 23.

Abstract

Today, using nanoparticle-based drug delivery systems has expanded to avoid anticancer side effects. Taxanes are important chemotherapeutic agents in the treatment of metastatic breast cancer. In this study, docetaxel (DTX)-loaded human serum albumin (HSA) nanoparticles (NPs) were prepared and characterized. Drug toxicity of the nanoparticles was measured by MTT assay with different drug concentrations (0.01, 0.1, 0.5, 1 and 5 μM) at different incubation times (24, 48 and 72 h). Expression of BAX/BCL2 mRNA levels was determined by real-time PCR. The size of NPs prepared and used in our study was about 147 nm with surface charge of -29.6 mV. Results obtained from MTT assay showed that 0.5 μM of free drug had 50 % toxicity on MCF-7 cells after 48-h incubation. Real-time PCR results showed an increase in expression of BAX and no change for BCL2. In conclusion, a significant overexpression of BAX gene and changes in BAX/BCL2 ratio were observed for DTX-loaded HSA nanoparticles compared with free DTX and may provide a potential therapy to inhibit anticancer drug resistance.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Cell Line, Tumor
  • Docetaxel
  • Female
  • Gene Expression / drug effects*
  • Humans
  • MCF-7 Cells
  • Nanoparticles / administration & dosage*
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • RNA, Messenger / genetics
  • Serum Albumin / administration & dosage*
  • Taxoids / administration & dosage*
  • bcl-2-Associated X Protein / genetics*

Substances

  • Antineoplastic Agents
  • BAX protein, human
  • BCL2 protein, human
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Messenger
  • Serum Albumin
  • Taxoids
  • bcl-2-Associated X Protein
  • Docetaxel